Different approaches have been designed to use IFN-λ as an efficacious therapeutic option with a more potent antiviral response than IFN type I. For example, the use of analogs of IFN-λ1 and IFN-λ3 have demonstrated high potency in activating IFN-stimulated response elements (80) as well as the use of recombinant bovine IFN-λ to treat COVID-19 (81). The gene discussed is IFNA1; the disease is COVID-19.